283 related articles for article (PubMed ID: 33489808)
1. A narrative review of evolving roles of radiotherapy in advanced non-small cell lung cancer: from palliative care to active player.
Zhou Y; Yu F; Zhao Y; Zeng Y; Yang X; Chu L; Chu X; Li Y; Zou L; Guo T; Zhu Z; Ni J
Transl Lung Cancer Res; 2020 Dec; 9(6):2479-2493. PubMed ID: 33489808
[TBL] [Abstract][Full Text] [Related]
2. International consensus on radiotherapy in metastatic non-small cell lung cancer.
Zhu Z; Ni J; Cai X; Su S; Zhuang H; Yang Z; Chen M; Ma S; Xie C; Xu Y; Li J; Ge H; Liu A; Zhao L; Rao C; Xie C; Bi N; Hui Z; Zhu G; Yuan Z; Wang J; Zhao L; Zhou W; Rim CH; Navarro-Martin A; Vanneste BGL; Ruysscher D; Choi JI; Jassem J; Chang JY; Kepka L; Käsmann L; Milano MT; Van Houtte P; Suwinski R; Traverso A; Doi H; Suh YG; Noël G; Tomita N; Kowalchuk RO; Sio TT; Li B; Lu B; Fu X
Transl Lung Cancer Res; 2022 Sep; 11(9):1763-1795. PubMed ID: 36248338
[TBL] [Abstract][Full Text] [Related]
3. Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses.
Ni J; Li G; Yang X; Chu L; Wang J; Li Y; Zou L; Li Y; Xie C; Zhu Z
Radiat Oncol; 2019 Mar; 14(1):44. PubMed ID: 30866974
[TBL] [Abstract][Full Text] [Related]
4. The Value of Radiotherapy for Advanced Non-Small Cell Lung Cancer With Oncogene Driver-Mutation.
Cui J; Li L; Yuan S
Front Oncol; 2022; 12():863715. PubMed ID: 35646640
[TBL] [Abstract][Full Text] [Related]
5. How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group.
Nyman J; Friesland S; Hallqvist A; Seke M; Bergström S; Thaning L; Lödén B; Sederholm C; Wagenius G
Lung Cancer; 2009 Jul; 65(1):62-7. PubMed ID: 19081652
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy for Oligometastatic Lung Cancer.
Bergsma DP; Salama JK; Singh DP; Chmura SJ; Milano MT
Front Oncol; 2017; 7():210. PubMed ID: 28975081
[TBL] [Abstract][Full Text] [Related]
7. Comparison of curative and palliative radiotherapy efficacy in unresectable advanced non-small cell lung cancer patients with or without metastasis.
Unlu I; Diniz G; Komurcuoglu B; Gayaf M; Gokce T; Karadogan I; Akcay C
Saudi Med J; 2006 Jun; 27(6):849-53. PubMed ID: 16758049
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.
Reboul FL
Hematol Oncol Clin North Am; 2004 Feb; 18(1):41-53. PubMed ID: 15005280
[TBL] [Abstract][Full Text] [Related]
9. Palliative extracranial radiotherapy in patients receiving immunotherapy for non-small cell lung cancer: a narrative review.
Kępka L
Transl Cancer Res; 2023 Jan; 12(1):163-176. PubMed ID: 36760380
[TBL] [Abstract][Full Text] [Related]
10. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic radiotherapy in targeted therapy treated oligo-metastatic oncogene-addicted (non-small-cell) lung cancer.
Giraud N; Abdiche S; Trouette R
Cancer Radiother; 2019 Jul; 23(4):346-354. PubMed ID: 31130373
[TBL] [Abstract][Full Text] [Related]
12. The evolving locally-advanced non-small cell lung cancer landscape: Building on past evidence and experience.
Méry B; Guy JB; Swalduz A; Vallard A; Guibert C; Almokhles H; Ben Mrad M; Rivoirard R; Falk AT; Fournel P; Magné N
Crit Rev Oncol Hematol; 2015 Nov; 96(2):319-27. PubMed ID: 26095618
[TBL] [Abstract][Full Text] [Related]
13. Perspective on treatment for unresectable locally advanced non-small cell lung cancer with oncogene-driven mutation: a narrative review.
Jiang L; Meng X; Zhao X; Xing L; Yu J
Transl Lung Cancer Res; 2020 Oct; 9(5):2137-2144. PubMed ID: 33209632
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases.
Saida Y; Watanabe S; Abe T; Shoji S; Nozaki K; Ichikawa K; Kondo R; Koyama K; Miura S; Tanaka H; Okajima M; Terada M; Ishida T; Tsukada H; Makino M; Iwashima A; Sato K; Matsumoto N; Yoshizawa H; Kikuchi T
Thorac Cancer; 2019 Nov; 10(11):2106-2116. PubMed ID: 31507098
[TBL] [Abstract][Full Text] [Related]
15. Combining Immunotherapy with Radiation Therapy in Non-Small Cell Lung Cancer.
Fitzgerald K; Simone CB
Thorac Surg Clin; 2020 May; 30(2):221-239. PubMed ID: 32327181
[TBL] [Abstract][Full Text] [Related]
16. Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy.
Economopoulou P; Mountzios G
Transl Lung Cancer Res; 2016 Dec; 5(6):588-598. PubMed ID: 28149754
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
Silvestri GA; Rivera MP
Chest; 2005 Dec; 128(6):3975-84. PubMed ID: 16354869
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of the unresectable non small cell lung carcinoma].
Spásová I
Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
20. Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer.
Turkaj A; Morelli AM; Vavalà T; Novello S
Front Oncol; 2018; 8():278. PubMed ID: 30140655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
